RecruitingNCT07548099

Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET/CT)

Sponsor

University of Pennsylvania

Enrollment

30 participants

Start Date

Apr 30, 2026

Study Type

OBSERVATIONAL

Conditions

Abdominal Aortic Aneurysm

Summary

This research study is being conducted to test how an imaging drug called 64Cu-DOTA-ECL1i can be used to image an abdominal aortic aneurysm. 64Cu-DOTA-ECL1i is a drug used with an imaging test called a PET/CT (Positron Emission Tomography/Computed Tomography). The aim is to collect data using a new imaging drug called 64Cu-DOTA-ECL1i that may be able to create images of inflammation in the aorta, which is thought to be important in how aneurysms grow and develop and to understand how consistent these scans are across time and what might affect the inflammation.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Participants will be at least 18 years of age
Have an established diagnosis of abdominal aortic aneurysm based on standard clinical criteria or are an age matched control with absence of known AAA.
Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria6

Females who are pregnant or breast feeding at the time of the PET/CT scan will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential before the injection of radiotracer.
Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
Patients with chronic renal disease whose GFR is less than 40 mL/min/1.73m² at the time of enrollment.
Documented allergy to iodinated contrast
Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
Less than 6 months life expectancy as deemed by the treating physician at the time of initial enrollment.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG64Cu-DOTA-ECL1i

The radiotracer 64Cu-DOTA-ECL1i will be used to assess the aortic wall in individuals with AAA and age-matched participants without a diagnosis of AAA as a control group.